TG Therapeutics Q2 net income drops to $7.8 million; revenue rises 70.26% to $240.3 million - TGTX News | RalliesTG Therapeutics Q2 net income drops to $7.8 million; revenue rises 70.26% to $240.3 million
T
TGTX• Full-year outlook
- Raised full-year 2026 revenue target to about $950 million, including BRIUMVI U.S. net product revenue target of about $890-$905 million.
- CEO Michael S. Weiss said BRIUMVI sales are tracking toward an about $1 billion annualized U.S. revenue run rate exiting 2026.
Q2 revenue and profit update
- TG Therapeutics posted Q2 2026 revenue of $240.3 million, including BRIUMVI U.S. net product revenue of $227.7 million, up about 64% y/y.
- Net income fell to $7.8 million from $28.2 million a year earlier, as R&D expense climbed to $95.3 million from $31.8 million.
- SG&A expense rose to $82.1 million from $55.6 million, driven by higher marketing and media spend plus commercialization-related personnel costs.
AVXL
•
